DOORS OF ELATION –
Nov. 13, 2021 – About 29.1% of patients who received the highest dose of psilocybin — the compound found in magic mushrooms — were in remission three weeks after treatment compared with 7.6% of those in the control group, according to Compass Pathways.
The patients that received 25-milligram — the highest dose of the drug in the study — also experienced a “highly statistically significant and clinically relevant reduction in depressive symptom severity after three weeks,” per Compass Pathways.
Patients who received the lower 10-milligram dose did not experience a statistically significant difference after three weeks.
The big picture: The results of the study, which included 233 patients across Europe and North America, come after the Food and Drug Administration granted Compass Pathways a breakthrough therapy designation, paving the way for a potentially accelerated drug approval process, per Stat.
Between the lines: The study also included data on patients who experienced adverse side effects from the drug.
Twelve patients reported treatment-emergent serious adverse events, including five who were in the 25-milligram group and six in the 10-milligram group.
